Lundbeck's bexicaserin receives Breakthrough Therapy Designation in China for the treatment of seizures in severe rare epilepsies

Contributed by: PR Newswire

Tags

H-Lundbeck-A/S

More Like This

Lundbeck to present new data on bexicaserin at upcoming congress, highlighting long-term impact on seizure frequency in patients with rare epilepsy

Lundbeck to present positive pipeline data at American Academy of Neurology (AAN) Annual Meeting

Breakthrough Therapy designation for Sanbexin sublingual tablets granted by the United States Food and Drug Administration

PR Newswire associated0

Breakthrough Therapy designation for Sanbexin sublingual tablets granted by the United States Food and Drug Administration

PR Newswire associated0

UCB presents latest research and clinical advancement across leading epilepsy portfolio at International Epilepsy Congress

Strong and durable effects 4 months after 2 doses (Graphic: Business Wire)

Cybin Receives FDA Breakthrough Therapy Designation for its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorder

Business Wire logo

First Patient Dosed in Beckley Psytech’s International Phase IIb Study of BPL-003, a Novel Synthetic Intranasal Formulation of 5-MeO-DMT, for Treatment Resistant Depression (TRD)

Lundbeck showcases new clinical migraine data, including long-term preventive effectiveness of Vyepti® (eptinezumab) in patients severely impacted by migraine